PILLAR ONE · TESTING METHODOLOGY
Peptriva Testing Methodology: a release rule, not a testing promise
Peptriva does not test some batches and publish the good ones. A lot cannot enter sellable stock until two certificates exist for it, and that condition sits in the order system rather than in a policy document. Scored 4.4 out of 5, held back by one thing.
- ASSAYS PER LOT
- 5
- CERTIFICATES PER LOT
- 2production, then independent
- ENDOTOXIN SPEC
- 0.05 EU/mLUSP <85>, in duplicate
- TESTING ROUNDS
- 1received 30 Jun, reported 2 Jul 2026
The lead finding
The strongest thing in Peptriva's testing programme is not the purity numbers, it is where the rule lives. A lot cannot enter sellable stock until both a production-facility certificate and an independent third-party certificate are on file, and that condition is enforced by the order system. Inventory does not move into a sellable state without it. Scored across this review's four surfaces, testing methodology takes 4.4 out of 5, with the deduction coming from a single fact stated at the end of this page: there has been one testing round, not a testing history.
The claim above describes Peptriva's own release rule, so the rule itself is Peptriva's word. What is not Peptriva's word is what the rule produces: the second certificate is issued by an outside laboratory that names itself, prints its own accession numbers, and can be contacted without going through Peptriva[2]. The rule is Peptriva's word. The output of the rule is not.
About Freedom Diagnostics, Peptriva's third-party lab
Freedom Diagnostics, of Franklin, Tennessee, United States, is the testing organisation of record on every published Peptriva certificate[2]. Certificates list the client as Peptriva Research and carry the signature of a Principal Chemist. Samples for the current round were received on 30 June 2026 and results were reported on 2 July 2026.
This review does not claim an accreditation for that laboratory. Peptriva's own storefront has asserted more than this in places, and these pages deliberately do not, because no scope certificate, scope number, or accrediting-body reference exists to point a reader at. The description that survives scrutiny is an independent third-party laboratory, named, at a stated address, with its documents published. That is a weaker claim than the storefront's and it is the one this review will defend.
That is exactly the kind of claim a cross-surface reading exists to catch. A statement appearing on a company's marketing surface and nowhere else is company copy. A certificate carrying an outside organisation's name, address and accession number is evidence.
The Peptriva testing programme versus the category baseline
The common practice in this category is periodic batch sampling: a supplier tests some production runs, publishes those certificates, and ships the rest on the strength of the pattern. That is cheaper and it is not dishonest, but it supports a different claim. Sampling supports "we test our products". A release rule supports "this lot did not become sellable until its certificate existed", and only the second can be checked against the vial in your hand.
No competitor is named anywhere on this network. The right-hand column describes what is common in the category rather than any particular company.
| Question to ask any supplier | Peptriva's published method | Common practice |
|---|---|---|
| Which lots are tested | Every lot, gated in the order system | Periodic batch sampling |
| How many certificates per lot | Two: production facility, then independent re-test | One, or none published |
| Which certificate is published | The independent one | Usually the production one |
| Is quantity measured | Yes, net content on every certificate | Rarely |
| Endotoxin standard | LAL under USP General Chapter <85>, run in duplicate | Varies, often unstated |
| Is the laboratory named | Yes, with an accession number per certificate | Often redacted or unnamed |
| Where does the rule live | A condition in the order system | Policy copy |
| Archive length | One round, thirteen lots | Years, hundreds of certificates |
The two-certificate rule works in two stages. The production facility tests and releases the batch first, and that certificate is held on file and is not published. On arrival at the United States distribution facility a sample goes to the independent laboratory for a full re-test, and that second certificate is the one published on the ledger[1].
One exemption is published rather than buried: the lab solvent clears on the independent certificate alone, because the production facility does not issue a certificate for an off-the-shelf USP solvent. A single named exemption is what a real operating rule looks like.
How many lots has Peptriva tested?
Thirteen lots, covered by fourteen certificates, with twelve rows on the public ledger[1]. Thirteen of the forty listed products are in stock and all thirteen are certified[5]. The extra certificate belongs to the solvent, which carries two accession numbers because two separate assays were run on it.
Eight of those thirteen lots are set out in full on the product-quality page, along with the lab solvent. The remaining four sit on a restricted tier where litigation risk in this category governs how they may be discussed, so no page here prints their figures. That is a publishing decision rather than a statement about their certificates, which are real and sit on the same public ledger[1].
What does the testing programme cover beyond purity?
Five assays run on every lot that reaches the independent laboratory, and the second and third are the ones that separate this panel from a purity-only certificate.
| Assay | Method | What it establishes |
|---|---|---|
| Identity | LC-MS | The material is the compound named on the label. |
| Purity | HPLC-UV, area percent | The headline purity figure on each certificate. |
| Net content | Measured mass in the vial | What is actually in the vial, weighed against what the label says. |
| Endotoxin | LAL, USP <85>, run in duplicate | Specification is 0.05 EU/mL or lower[6]. |
| Appearance | Visual | Recorded on every certificate. |
Net content is the assay worth pausing on. Purity is a ratio, and a ratio cannot detect an underfilled vial: material at 99.8 percent purity in a vial holding well under the labelled quantity produces a certificate that looks excellent. Weighing the contents closes that hole, and it is the assay most likely to be missing from a certificate published elsewhere in this category.
Identity by LC-MS answers the question most readers actually have, which is whether the vial contains the compound on the label at all. Appearance is the cheapest check on the panel and the only one a buyer can repeat: the GHK-Cu lot is recorded as a blue lyophilized powder[1], the expected visual for a copper complex.
What is USP <85> and why does it matter?
USP General Chapter <85> is the United States Pharmacopeia's Bacterial Endotoxins Test, a published pharmacopoeial standard rather than a house method[6]. Peptriva's endotoxin assay is run against it by LAL, in duplicate, with a specification of 0.05 EU/mL or lower[1].
It matters for a structural reason rather than a chemical one. A result reported against a named public standard can be looked up and checked against a number nobody at the supplier chose. A result reported against an unstated method cannot be interpreted at all. That is the test this review applies everywhere: a claim anchored to an outside reference scores, and a claim anchored to itself does not.
Running it in duplicate matters for a smaller reason: one reading is a measurement, two are a measurement with a consistency check, and the certificate records both.
The gap: one testing round, not a testing history
Every certificate on the ledger comes from one submission. One receipt date, 30 June 2026. One report date, 2 July 2026[2]. That is the deduction in this pillar's score and it is not recoverable by argument.
Complete coverage and demonstrated cadence are different properties and should not be traded for one another. Peptriva can say today that every lot in stock carries an independent certificate. It cannot say it has done so repeatedly over time. A supplier with years of archived rounds has something Peptriva does not have, and no reading of the current ledger supplies it.
What would close the gap is specific and watchable from the ledger: a second and third round on new lot codes, with new receipt and report dates[1]. That converts coverage into cadence.
Two further limits belong here rather than in a footnote. No accreditation scope is published for the laboratory, so none is asserted. And the panel contains no sterility assay: the five assays above are the whole panel, and the published terms state the material is not sterile[3].